| 词条 | Ambit Biosciences |
| 释义 |
Ambit was an American pharmaceutical company focused on development of kinase inhibitor therapeutics to treat a variety of human diseases.[1]{{rp|3}}[2] {{As of|2014|03}}, the company was based in San Diego, California and consisted of a single facility.[3]{{rp|58}} Ambit made an initial public offering in May 2013[3] and was listed on the NASDAQ exchange under the symbol "AMBI".[4] Ambit was acquired by Daiichi Sankyo in 2014 and is no longer traded on the NASDAQ exchange. Products{{As of|2014|03}}, three products were under development, of which quizartinib was their lead drug candidate.[1]{{rp|3}}Business model{{As of|2014|3}}, Ambit sought to develop new therapeutics through internal, proprietary research, which is evidenced by their pipeline of three products consisting entirely of internally developed therapeutics.[1]{{rp|3}} Further, Ambit aimed to be a full life cycle pharmaceutical company by conducting discovery, development and further commercialization of therapeutics.[1]{{rp|3}}Among the firms who invested heavily in Ambit prior to its initial public offering was Foresite Capital in January 2013.[4] In November of 2014, Ambit was acquired by Daiichi Sankyo.[5] References1. ^1 2 3 {{Cite web|url=https://www.sec.gov/Archives/edgar/data/1131543/000119312514108100/d667162d10k.htm|title=Form 10-K: Ambit Biosciences Corporation. Commission file number: 001-35919|last=|first=|date=March 20, 2014|website=EDGAR|publisher=U.S. Securities and Exchange Commission|archive-url=|archive-date=|dead-url=|access-date=2017-06-27}} 2. ^The SEC 10K submission for 2013 indicates that the company is a "biopharmaceutical" company, which implies that they are primarily developing biopharmaceuticals; however their lead product is a small molecule therapeutic, calling into question the term used in the SEC submission. 3. ^1 {{Cite journal|last=Huggett|first=Brady|date=December 2013|title=Burning bright|url=http://www.nature.com/nbt/journal/v31/n12/full/nbt.2766.html|journal=Nature Biotechnology|language=en|volume=31|issue=12|pages=1068–1071|doi=10.1038/nbt.2766}} 4. ^1 {{Cite news|url=http://www.xconomy.com/san-francisco/2014/04/01/foresite-capital-reloads-with-new-300m-late-stage-biotech-fund/|title=Foresite Capital Reloads With New $300M Late-Stage Biotech Fund|last=Fidler|first=Ben|date=2014-04-01|work=Xconomy|access-date=2017-06-27|archive-url=|archive-date=|dead-url=|language=en-US}} 5. ^{{Cite news|url=http://www.sandiegouniontribune.com/business/biotech/sd-me-japan-biotech-20170116-story.html|title=Local biotech turning to Japan for partnerships|last=Fikes|first=Bradley J.|date=2017-01-16|work=The San Diego Union-Tribune|access-date=2017-06-27|archive-url=|archive-date=|dead-url=|language=en-US}} Notes{{reflist|group=n}}{{med-company-stub}} 5 : Companies listed on NASDAQ|Companies based in San Diego|Pharmaceutical companies of the United States|Health care companies based in California|Daiichi Sankyo |
| 随便看 |
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。